Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Engl

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Clinical and Experimental Immunology|March 18, 2008
Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficienciesR Gustafson, A Gardulf, S Hansen, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 29, 2016
Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia AE S Mullins, O Stasyshyn, M T Alvarez-Román, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 10, 2001
An approach to study the viral safety of plasma-derived products in previously treated, non-infected patientsE Berntorp, P Petrini, G Dockter, et al.
Hamostaseologie|December 18, 2013
Recruitment update of AHEADJ Oldenburg, R Zimmermann, A Huth-Kühne, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 11, 2007
Evaluation of pharmacokinetics, efficacy and safety of Immunate solvent detergent in previously treated patients with severe haemophilia AL Nemes, T Lissitchkov, A Klukowska, et al.
Clinical and Experimental Immunology|September 11, 2016
Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficienciesM Borte, G Kriván, B Derfalvi, et al.
Acta Haematologica|February 29, 2008
Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III studyL Nemes, T Lissitchkov, G Dobaczewski, et al.
European Cytokine Network|February 12, 2010
Influence of significant weight loss on serum matrix metalloproteinase (MMP)-7 levelsClaudia Ress, Alexander Tschoner, Christian Ciardi, et al.
AIDS (London, England)|August 28, 1999
Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study GroupF D Goebel, J W Mannhalter, R B Belshe, et al.
Vox Sanguinis|April 26, 2006
Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemiaJ Björkander, J Nikoskelainen, H Leibl, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical and Experimental Immunology|March 18, 2008
Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficienciesR Gustafson, A Gardulf, S Hansen, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 29, 2016
Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia AE S Mullins, O Stasyshyn, M T Alvarez-Román, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 10, 2001
An approach to study the viral safety of plasma-derived products in previously treated, non-infected patientsE Berntorp, P Petrini, G Dockter, et al.
Hamostaseologie|December 18, 2013
Recruitment update of AHEADJ Oldenburg, R Zimmermann, A Huth-Kühne, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 11, 2007
Evaluation of pharmacokinetics, efficacy and safety of Immunate solvent detergent in previously treated patients with severe haemophilia AL Nemes, T Lissitchkov, A Klukowska, et al.
Clinical and Experimental Immunology|September 11, 2016
Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficienciesM Borte, G Kriván, B Derfalvi, et al.
Acta Haematologica|February 29, 2008
Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III studyL Nemes, T Lissitchkov, G Dobaczewski, et al.
European Cytokine Network|February 12, 2010
Influence of significant weight loss on serum matrix metalloproteinase (MMP)-7 levelsClaudia Ress, Alexander Tschoner, Christian Ciardi, et al.
AIDS (London, England)|August 28, 1999
Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study GroupF D Goebel, J W Mannhalter, R B Belshe, et al.
Vox Sanguinis|April 26, 2006
Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemiaJ Björkander, J Nikoskelainen, H Leibl, et al.
Pageof 2